ASX Share rice
Wed 05 Aug 2020 - 11:49:am (Sydney)

RMD Share Price

RESMED INCRMDHealth Care Equipment & Services

RMD Company Information

Name:

ResMed Inc

Sector:

Healthcare

Industry:

Medical Instruments & Supplies

Address:

9001 Spectrum Center Boulevard San Diego CA United States 92123

Phone:

858-836-5000

Full Time Employees:

7240

Founder & Non-Exec. Chairman:

Dr. Peter C. Farrell A.M., Ph.D., BE (Hons), ScD, AM

CEO & Director:

Mr. Michael J. Farrell BE, SM, MBA

Pres & COO:

Mr. Robert A. Douglas

Chief Financial Officer:

Mr. Brett A. Sandercock

Pres of Sleep & Respiratory Care Bus.:

Mr. James R. Hollingshead Ph.D.

Company Overview:

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software solutions that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates through two segments, Sleep and Respiratory Care, and Software as a Service (SaaS). It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides humidifiers, carry bags, and breathing circuits; data communications and control products, such as AirView Diagnostics, EasyCare, ResLink, ResControl, ResControl II, TxControl, ResScan, and ResTraxx modules; U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as S+, connectivity module, and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and healthcare-first and matrixcare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 120 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

RMD Share Price Information

Shares Issued:

1.45B

Market Capitalisation:

$40.88B

Dividend per Share:

$0.27

Ex Dividend Date:

2020-02-12

Dividend Yield:

0.96%

Revenue (TTM):

$2.89B

Revenue Per Share (TTM):

$2.01

Earnings per Share:

$0.3523

Profit Margin:

0.1773

Operating Margin (TTM):

$0.26

Return On Assets (TTM):

$0.11

Return On Equity (TTM):

$0.24

Quarterly Revenue Growth (YOY):

0.162

Gross Profit(TTM):

$1.54B

Diluted Earnings Per Share (TTM):

$0.3523

QuarterlyEarnings Growth(YOY):

0.534

RMD CashFlow Statement

CashFlow Date:

2019-06-30

Investments:

$-1,075,706,000

Change To Liabilities:

$-27,278,000

Total Cashflow From Investing Activities:

$-1,075,706,000

Net Borrowings:

$807.49M

Net Income:

$404.59M

Total Cash From Operating Activities:

$459.05M

Depreciation:

$150.80M

Other Cashflow From Investing Activities:

$-264,000

Dividends Paid:

$-211,712,000

Change To Inventory:

$-84,188,000

Change To Account Receivables:

$-18,013,000

Sale Purchase Of Stock:

$-22,844,000

Capital Expenditures:

$77.34M

RMD Income Statement

Income Date:

2019-06-30

Income Before Tax:

$518.85M

Net Income:

$404.59M

Gross Profit:

$1.54B

Operating Income:

$635.99M

Interest Expense:

$36.16M

Income Tax Expense:

$114.26M

Total Revenue:

$2.61B

Total Operating Expenses:

$1.97B

Cost Of Revenue:

$1.07B

RMD Balance Sheet

Balance Sheet Date:

2019-06-30

Intangible Assets:

$521.95M

Total Liabilities:

$2.04B

Total Stockholder Equity:

$2.07B

Other Current Liabilities:

$244K

Total Assets:

$4.11B

Common Stock:

$575K

Other Current Assets:

$371K

Retained Earnings:

$2.44B

Other Liabilities:

$220.64M

Good Will:

$1.86B

Other Assets:

$144.36M

Cash:

$147.13M

Total Current Liabilities:

$555.99M

Short-Term Debt:

$11.99M

Property - Plant & Equipment:

$387.46M

Net Tangible Assets:

$-306,206,000

Long-Term Investments:

$52.10M

Total Current Assets:

$1.15B

Long-Term Debt:

$1.26B

Net Receivables:

$528.48M

Short-Term Investments:

$2.96B

Inventory:

$349.64M

Accounts Payable:

$115.73M

Non Currrent Assets (Other):

$2.96B

Short-Term Investments:

$2.96

Non Current Liabilities (Other):

$2.06M

Non Current Liabilities Total:

$1.48B

RMD Share Price History

RMD News

04 Aug, 2020
Many Medical Product stocks might have succeeded in mitigating coronavirus-led downsides banking on huge market adoption of their COVID-19-related healthcare-support products in the second quarter.
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
ResMed (RMD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
03 Aug, 2020
ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
02 Aug, 2020
A look at the shareholders of ResMed Inc. (NYSE:RMD) can tell us which group is most powerful. Insiders often own a...
29 Jul, 2020
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
28 Jul, 2020
Is (RMD) Outperforming Other Medical Stocks This Year?
21 Jul, 2020
ResMed (RMD) possesses solid growth attributes, which could help it handily outperform the market.
16 Jul, 2020
ResMed (RMD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
15 Jul, 2020
ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2020 on Wednesday, August 5, 2020, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss these results. Other forward-looking and material information may also be discussed during this call.
14 Jul, 2020
Some investors are getting increasingly worried about the outlook for technology and big growth stocks after a massive rally which has pushed the Nasdaq Composite index to record highs despite the coronavirus-inflicted economic damage. Few can complain about the performance of the S&P 500 Growth index, whose components range from Netflix Inc to medical device maker ResMed Inc and is up more than 10% for the year to date while the broad S&P 500 remains down 2% over the same time. Instead, investors say the popularity of tech and growth stocks at a time of global economic uncertainty has left their valuations stretched and primed them for a decline.
10 Jul, 2020
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]
02 Jul, 2020
ResMed (RMD) possesses solid growth attributes, which could help it handily outperform the market.
30 Jun, 2020
13:23
Yahoo! Finance
Given strong dividend growth and big money signals, these stocks could be worth a spot in a yield-oriented portfolio.
25 Jun, 2020
Investors continue to be upbeat about ResMed (RMD) owing to its strong emphasis on product development and consistent high demand for its critical care products.
19 Jun, 2020
The stock market swooned after reports said Apple is closing some stores due to a spike in coronavirus cases.
10 Jun, 2020
18:08
Yahoo! Finance
In the current session, ResMed Inc. (NYSE: RMD) is trading at $166.76, after a 3.24% increase. Over the past month, the stock increased by 1.45%, and in the past year, by 39.62%. With performance like this, long-term shareholders optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.Assuming that all other factors are held constant, this could present itself as an opportunity for shareholders trying to capitalize on the higher share price. The stock is currently below from its 52 week high by 6.31%.The P/E ratio measures the current share price to the company's earnings per share. It is used by long-term investors to analyze the company's current performance against its past earnings, historical data and aggregate market data for the industry or the indices, such as S&P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also shows that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future.Depending on the particular phase of a business cycle, some industries will perform better than others.Compared to the aggregate P/E ratio of the 78.36 in the Medical Instruments & Supplies industry, ResMed Inc. has a lower P/E ratio of 45.88. Shareholders might be inclined to think that they might perform worse than its industry peers. It's also possible that the stock is undervalued.There are many limitations to price to earnings ratio. It is sometimes difficult to determine the nature of the earnings makeup of a company. Shareholders might not get what they're looking for, from trailing earnings.See more from Benzinga * P/E Ratio Insights for Toro * P/E Ratio Insights for TrueCar * Price Over Earnings Overview: Eventbrite(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
03 Jun, 2020
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer, will participate in a virtual fireside chat at the William Blair 40th Annual Growth Stock Conference on Wednesday, June 10, 2020, beginning at approximately 12:00 p.m. (Central Daylight Time) via video webcast.
30 May, 2020
ResMed (RMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

RMD Dividend Payments

EX-Date Dividend Amount
2012-09-03$0.0139
2012-11-13$0.0139
2013-02-12$0.0140
2013-05-15$0.0147
2013-08-14$0.0234
2013-11-12$0.0225
2014-02-12$0.0236
2014-05-16$0.0271
2014-08-19$0.0256
2014-11-17$0.0325
2015-02-09$0.0308
2015-05-19$0.0302
2017-05-10$0.0330
2017-08-16$0.0440
2017-11-07$0.0350
2018-02-06$0.0350
2018-05-09$0.0350
2019-08-14$0.0390
2019-11-05$0.0390
2020-02-11$0.0390

RMD Dividends (last 8 Years)